Overview Diabetes In China Biosensor Technology Team
Overview Diabetes In China Biosensor Technology Team

diabetes in China

China has the world’s largest diabetic population and it continues to grow at an alarming rate.

Diabetes is an increasing burden on the Chinese healthcare system and it is estimated diabetes accounts for 13% of medical expenditure in China2.

The number of people affected by diabetes has spiked in recent years and is expected to reach 150 million by 20402.

114.4 million

Mainland China has the highest number of people with diabetes in the world; the estimated prevalence of diabetes in China is 10.9%.1

That’s 25% of the world’s diabetic population.

493.4 million

Estimated number of Chinese adults that have pre-diabetes, an estimated prevalence rate of 50.1%.3

61 million

China has 61 million adults with undiagnosed diabetes.1

US$110 billion

Diabetes related health expenditure in China in 2017 alone.1

842,993 deaths

842,993 deaths due to diabetes in China in 2017 (21% of total global deaths due to diabetes).

33.8% of those deaths occurred in people under 60.1

1.2 billion

We know there are 114 million diabetic patients in China, assume 1% of these patients use a glucose biosensor strip 3 times per day, that’s over 1.2bn strips per annum.
These statistics illustrate the enormity of diabetes as a public health problem in China.

The big challenge now for China is to raise public awareness of the symptoms of diabetes and the benefits of early diagnosis.

Medical complications and potentially hospitalizations are far more likely if diabetes is undiagnosed or poorly monitored and managed.

“The costs of diabetes (and other lifestyle NCDs) will overwhelm the healthcare system”4
Dr. Bernhard Schwartländer
A World Health Organization Representative in China, 2016
THE PROBLEM
Patients avoid frequent glucose testing as the current method is invasive, painful and inconvenient
Invasive finger stick devices must be used several times a day
Lancing of the finger to draw blood can be painful and lead to risk of infection
The blood sample is then placed on a disposable test strip that is inserted into a blood glucose meter
Once the reading has been taken, used lancet and blood strips constitute a biohazard and must be disposed of
THE SOLUTION
The non-invasive, pain-free and easy-to-use Saliva Glucose Biosensor
Bring the Saliva Glucose Biosensor in contact with saliva
Glucose level reading is displayed on a smart device
View results and compare historic glucose levels through interactive app
Cloud data processing and AI interface
For illustrative purposes only and has yet to receive regulatory approval in any jurisdiction
technology
“What’s really exciting is that this technology that we have
developed is actually a platform technology...” Professor Paul Dastoor, University of Newcastle, Australia
Team
The GBSG Management Team and Board of Directors have significant global experience in the development of medical devices, clinical devices and launch strategy.
Directors
Mr. Harry Simeonidis
Mr. Harry Simeonidis
Chief Executive Officer
Mr. Harry Simeonidis has more than 25 years’ experience in global executive management roles in healthcare, pharmaceutical, and life sciences businesses. His previous roles include CEO of Australia and New Zealand at GE Healthcare and more recently, General Manager for Surgery Asia Pacific at GE Healthcare.

Mr Simeonidis is currently Executive Director and General Manager of Farmaforce Ltd.
Dr. Jean-Claude Becker
Dr. Jean-Claude Becker
Chief Operating Officer,
Executive Vice President and Director
J.C. Becker, M.D. is a global researcher with expertise in developing and positioning innovative products.

For the last five years Dr. Becker has been an independent consultant in the pharmaceutical and biomedical industries. Before that Dr. Becker was Group Director Global Clinical Research in Immunology at Bristol-Myers Squibb for 12 years. He also has successfully conducted global clinical trials towards obtaining regulatory approvals as well as projects to position and profile biologics/drugs with post-approval studies to achieve marketing and commercial objectives.

Prior to his work at Bristol-Myers Squibb, Dr. Becker held senior research positions at other large pharmaceutical companies, including Sandoz and Pfizer. Dr. Becker received his M.D. from the Paris VI University in France. He has been widely published in major scientific publications and medical journals and has reported at major international congresses for more than 25 years.
Victoria Gavrilenko
Victoria Gavrilenko
Operations Manager, Secretary,
Treasurer and Director
Victoria Gavrilenko is Operations Manager, Secretary, Treasurer, and Director. Ms Gavrilenko is based full-time at the company's New York City headquarters. Before this Ms Gavrilenko was Office Manager at the New York City offices of iQ capital. Ms Gavrilenko graduated from California State University San Marcos.
Mr. Jonathan Hurd
Mr. Jonathan Hurd, CAMS
Chairman of the Board
Mr. Hurd is the current CEO and founder of Asgard Regulatory Group, an organisation that provides broker-dealer and investment adviser compliance consulting services in the U.S. and internationally. Previously Mr. Hurd was the Chief Compliance Officer for several financial institutions and has served on the Board of Directors for numerous investment companies. Mr. Hurd was a Supervisor of Examiners at FINRA and has conducted large-scale enforcement cases jointly with the Justice Department and the FBI.
Dr. John Caminis
Dr. John Caminis M.D.
Director
Dr. John Caminis is a pharmaceutical physician with a successful track record in clinical development and medical affairs and has wide-ranging experience in the design and execution of clinical trials in diverse therapeutic areas including metabolic/metastatic bone disease, oncology, gastroenterology, pain, immunology, infectious disease, and dermatology. He has made many contributions in providing medical direction for new products and business development efforts.

Dr. John Caminis is currently Therapeutic Area Head in Global Drug Safety for Shire Pharmaceuticals.
Dr. Yong-Jiang Hei
Dr. Yong-Jiang Hei M.D., Ph.D (Pharmacology)
Director
Dr. Yong-Jiang Hei is the former Executive Medical Director of AMGEN China. He has extensive expertise and hands-on experience in clinical strategy, clinical trial design, and conduct and regulatory filings. He currently serves as Chief Medical Officer at biopharmaceutical company Ambrx.
Scientific Advisory Board
Dr. George Syrmalis
Dr. George Syrmalis MD, PhD, FACNP, MAAPP
Executive Chairman and CEO of
The iQ Group Global
Dr. Syrmalis is trained in Nuclear Medicine-radiation immunology and established iQnovate, part of The iQ Group Global, in 2011. Previously, Dr. Syrmalis founded and led as CEO and Chairman The Bionuclear Group SA, (1995-2005) incorporating Antisoma SA, Bionuclear Institute of Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. He developed a business model by addressing unmet clinical needs and leveraging on synergies between Bionuclear Group companies.
  • Antisoma SA: focused on development of novel biologic compounds both radio diagnostic and radio therapeutic in the area of oncology.
  • Bionuclear Institute for Diagnosis and Therapy SA: expanded into medical centers-renal dialysis clinics and the development of Europe’s most prominent reference pathology service.
  • Bionuclear Research and Development SA: novel and generic radiopharmaceutical production.
  • Vitalcheck SA: Research, development and commercialization of point of care tests for professional and layman use. From 2005 onwards George continued his career as advisor to the Biopharmaceutical industry, advising on translational clinical trials, biomarkers and strategy to commercialize novel biologic entities in the areas of oncology, epilepsy and autoimmune diseases.
Professor Paul Dastoor
Professor Paul Dastoor - Inventor
PhD, University of Cambridge, Bachelor of Arts (Honours), University of Cambridge
Paul Dastoor is a Professor in Physics in the School of Mathematical and Physical Sciences and the director of the Centre for Organic Electronics at the University of Newcastle in Australia. He received his B.A. degree in Natural Sciences from the University of Cambridge in 1990 and his PhD in Surface Physics, also from the University of Cambridge, in 1995.

His expertise covers surface analysis, electron spectroscopy, thin film growth, organic electronics, organosilane chemistry, polymer films, atom beam optics and microscopy and medical devices. His research can be grouped in 3 main areas: (1) Helium Atom Microscopy, (2) Polymer Adsorption on Metal Surfaces and (3) Organic Electronic Devices. Helium Atom Microscopy Atomic scattering from surfaces has matured into a unique analytical technique for the study of formation of thin film structures.

1. International Diabetes Federation. IDF Diabetes Atlas 8th edn. Brussels, Belgium: International Diabetes Federation, 2017

2. http://www.wpro.who.int/china/mediacentre/releases/2016/20160406/en/

3. Prevalence and Control of Diabetes in Chinese Adults, The Journal of the American Medical Association, September 2013

4. WHO Global Report on Diabetes, 2016

info@gbsgreaterchina.com

Glucose Biosensor Systems (Greater China) Inc and each of their related bodies corporate, directors, employees and consultants (collectively, the Biosensor Group) each do not guarantee, and do not accept any liability whatsoever arising from or connected to, the accuracy, reliability, currency or completeness of any material contained within this website and any document in connection with it (Materials). Although the information in the Materials has been obtained from, and is based upon, information and sources that the Biosensor Group believes to be reliable, it does not guarantee its accuracy, and any such information may be incomplete or condensed. The Materials (collectively or individually) are not intended as an offer or solicitation with respect to the purchase or sale of any security and may not be reproduced or redistributed in whole or in part to any other person. Recipients should seek appropriate independent professional advice prior to relying on, or entering into any commitment based upon, Materials.
  

733 Third Avenue, Floor 16, New York, NY 10017 © Copyright 2018 Glucose Biosensor Systems (Greater China) Holdings Inc. All rights reserved